metaEvidence - mapping review

meta|evidence oncology

Living systematic review and meta-analysis

breast cancer - HR positive
es-BC - HR positive - (neo)adjuvant (NA) 2
es-BC - HR-positive - 1st line (L1) 1
la/mBC - HR positive 2
la/mBC - HR positive - (neo)adjuvant (NA) 3
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1) 13
la/mBC - HR positive - L1 - PIK3CA mutant 1
la/mBC - HR-positive - 2nd line (L2) 20
la/mBC - HR positive - L2 - all population 1
la/mBC - HR positive - L2 - PIK3CA mutant 1

AKT inhibitor
capivasertib based treatment
capivasertib plus paclitaxel
ipatasertib based treatment
ipatasertib plus paclitaxel
antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
aurora kinase inhibitors
alisertib plus paclitaxel
biguanide
metformin
celecoxib plus endocrine therapy
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus aromatase inhibitor
abemaciclib plus endocrine therapy
abemaciclib plus fulvestrant
dalpiciclib plus fulvestrant
palbociclib based treatment
palbociclib plus endocrine therapy
palbociclib plus fulvestrant
palbociclib plus letrozole
ribociclib based treatment
ribociclib plus endocrine therapy
ribociclib plus fulvestrant
ribociclib plus letrozole
gene alteration target therapy
FGFR (2/3) gene alteration targeted therapy
FGFR inhibitors
dovitinib based treatment
dovitinib plus fulvestrant
HDAC inhibitor
entinostat plus exemestane
tucidinostat based treatment
tucidinostat plus exemestane
HER inhibitor
HER2 inhibitor
trastuzumab based treatment
trastuzumab plus endocrine therapy
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib plus fulvestrant
lapatinib plus letrozole
IGF-1R inhibitors
dalotuzumab plus ridaforolimus plus exemestane
ganitumab plus endocrine therapy
Immunostimulant
vaccine
OBI-822/OBI-821 plus cyclophosphamide
mTOR inhibitors
sapanisertib plus fulvestrant
phosphoinositide 3-kinase (PI3K) inhibitor
alpelisib based treatment
alpelisib plus fulvestrant
alpelisib plus letrozole
buparlisib based treatment
buparlisib plus fulvestrant
buparlisib plus letrozole
taselisib based treatment
taselisib plus fulvestrant
taselisib plus letrozole
VEGF(R) inhibitor
cediranib plus fulvestrant

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs capecitabine
vs taxanes
vs paclitaxel
vs endocrine therapy
vs aromatase inhibitor
vs exemestane
vs exemestane plus ridaforolimus
vs fulvestrant
vs letrozole
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs trastuzumab plus chemotherapy
vs trastuzumab plus endocrine therapy
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

graph table EGM comparisons

click on circles to display study description...

NEO-ORB (wild type cohort), 2019 NCT01923168

alpelisib plus letrozole (n=131) vs. letrozole (n=126)

randomized controlled trial

Studied treatment

alpelisib plus letrozole
alpelisib: PO 300mg/per day / letrozole: PO 2.5mg/per day (all trt were self-administered)

Control treatment

letrozole
letrozole: PO 2.5mg/per day (all trt were self-administered)

Patients

la/mBC - HR positive - (neo)adjuvant (NA)

Enrollment in the buparlisib arm was discontinued on December 22, 2015, due to the nontolerable toxicity profile associated with buparlisib; patients randomized after this date were assigned 1:1 to either alpelisib plus letrozole or placebo plus letrozole.

Method

double blind

at 87 centers in 17 countries

P2 / Bayesian methods

Remark

Exploratory results

NEO-ORB (mutant cohort), 2019 NCT01923168

alpelisib plus letrozole (n=-9) vs. letrozole (n=126)

randomized controlled trial

Studied treatment

alpelisib plus letrozole
alpelisib: PO 300mg/per day / letrozole: PO 2.5mg/per day (all trt were self-administered)

Control treatment

letrozole
letrozole: PO 2.5mg/per day (all trt were self-administered)

Patients

la/mBC - HR positive - (neo)adjuvant (NA)

Enrollment in the buparlisib arm was discontinued on December 22, 2015, due to the nontolerable toxicity profile associated with buparlisib; patients randomized after this date were assigned 1:1 to either alpelisib plus letrozole or placebo plus letrozole.

Method

double blind

at 87 centers in 17 countries

P2 / Bayesian methods

Remark

Exploratory results

powered by vis.js Network